Katzmair cop2011 - evidence based mapping
-
Upload
roberto-pineda -
Category
Health & Medicine
-
view
351 -
download
5
description
Transcript of Katzmair cop2011 - evidence based mapping
![Page 1: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/1.jpg)
Evidence Based Mapping Network Strategy Consulting in KOL Management, Marketing, Regulatory & Market Access.
Harald Katzmair
6/6/2011 1 © 2011 FAS.research
![Page 2: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/2.jpg)
FAS.research is a Social Network Analytics & Strategies company. FAS.research maps key-drivers and key-influencers to leverage the power of networks for KOL management, public affairs, key account management and social change.
6/6/2011 © 2011 FAS.research 2
![Page 3: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/3.jpg)
Clients (Selection)
6/6/2011 © 2011 FAS.research 3
![Page 4: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/4.jpg)
6/6/2011 © 2011 FAS.research 4
Rx
![Page 5: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/5.jpg)
How does the Pharma Business work?
Perceived medical need and value
Pri
ce
![Page 6: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/6.jpg)
Drug from Pharma Company ABC
Perceived medical need and value
Pri
ce
Rx
![Page 7: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/7.jpg)
Goal Pharma Company ABC
Perceived medical need and value
Pri
ce
Huge therapeutic deficit Huge pain and suffering No alternatives Low complexity Evidence
![Page 8: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/8.jpg)
Goal Pharma Company ABC
Perceived medical need and value
Pri
ce Massive development
and research costs Secure medical
progress High service level
(hotlines, value adds) General economic
savings through reduced follow up costs
![Page 9: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/9.jpg)
Goal Pharma Company ABC
Perceived medical need and value
Pri
ce
Rx Rx High value block buster
drug
![Page 10: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/10.jpg)
Goal Payor ABC
Perceived medical need and value
Pri
ce
Rx
![Page 11: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/11.jpg)
Goal Payor ABC
Perceived medical need and value
Pri
ce
Commoditize perceived medical value and need
Not enough evidence in all fields
Existing alternatives High complexity Me-too product
(Pseudo Innovation) Therapeutic guidelines Competitors product
shows more evidence and value
Rx
![Page 12: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/12.jpg)
Goal Payor ABC
Perceived medical need and value
Pri
ce
Re
du
ce d
rug
pri
ces
(Sic
k fu
nd
s)
FRP Guidelines Rebates
Rx
![Page 13: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/13.jpg)
Goal Payors and Competitors
Perceived medical need and value
Pri
ce
Rx
Biggest bang for the buck
Commoditized markets (Scaling Effects)
Decreasing health care costs
![Page 14: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/14.jpg)
Strategy of Payor ABC
Perceived medical need and value
Pri
ce
Product B
Product C Product D
Product A
Challenge Evidence Discredit as Me-too
product (Pseudo Innovation)
Show Alternatives
![Page 15: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/15.jpg)
Pharma Portfolio Strategies
Perceived medical need and value
Pri
ce
Based on position of drug different strategies Qualitative Increase perception of medical value and need (quality) strategy Quantitative Maximize price (avoid, delay FRP, rebate contracts negotiation excellence)
Product B
Product C Product D
Product A
![Page 16: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/16.jpg)
Challange
Perception of value and need outcome of a social construction and negotiations?
Who are the people, institutions, frames and stories that shape the value perception of a drug?
How robust and stable are those constellations?
What are the right strategies and tactics to improve the value perception?
Stories, frames, domains, context?
Key Opinion Leader? „Followers“?
6/6/2011 16
![Page 17: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/17.jpg)
Social Networks in Business-to-Doctor (B2D)
Pharma-to-Doctor Doctor-to-External
Doctor-to-Doctor Doctor-to-Altera
Peer Group Networks
Associations
Research Groups (Hospital)
Informal Group
…
Patient organizations
Networks
Informal Groups
Sick Funds
Quality Circle
Research Groups
Focus Groups
Advisory Boards
Informal Groups
…
Specialists/ Hospital Re+ Ug+
Specialists, GPs + Pharma
Opinion Leaders ++ Pharma
GPs + Ug+
Patient, doctor, family
members…
Based on van Lier, 2007
![Page 18: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/18.jpg)
Key Opinion Leader (KOL)
6/6/2011 18 © 2008 FAS.research
![Page 19: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/19.jpg)
6/6/2011 © 2008 FAS.research 19
![Page 20: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/20.jpg)
Influence Drug Perception and Value
• Assessing drug efficacy (evidence)
• Forming public opinion
• Lobbying (regulatory
& reimbursement
Evidence and Guidelines
Reimbursement
Clinical Trials
• Conducting, Supervising
Clinical Trials
• Advising company
• Lobbying (regulatory &
reimbursement)
Regulatory Acceptance and FRPs
• Building early trust
• Running clinical trials
• Conducting early research
use for: use for: use for:
KOL Segmentation
Functional KOL Segmentation
Global KOL Local KOL Emerging KOL
Clinical Trials
![Page 21: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/21.jpg)
Evidence based validation cycle
ok
check ok
check
![Page 22: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/22.jpg)
low high
low
h
igh
Potential Network Partners
Invest (selectively)
Unnecessary Network Actors
Disinvest
Key Network Partner
Develop & Invest
Peripheral Network Actors
Hold
Impact on value
perception of Drug RX
Access and win-win opporunities
![Page 23: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/23.jpg)
![Page 24: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/24.jpg)
![Page 25: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/25.jpg)
The Myth of Influence
![Page 26: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/26.jpg)
Is really everybody a receptive match?
![Page 27: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/27.jpg)
Who is receptive / susceptible?
![Page 28: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/28.jpg)
I. Awareness 1. Hears drug story (media, colleagues etc.)
2. Understands value proposition
II. Conviction
3. Likes story and value prop (matches with need)
4. Talks with colleagues and KOLs
5. Experiences consensus in network
III. Decision 6. Intents to prescribe
IV. Action 7. Prescribes
V. Confirmation 8. Positive / Negative experiences
9. Passes on experience
Prescribing as Process
6/6/2011 28 © 2010 FAS.research
![Page 29: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/29.jpg)
Who is receptive / susceptible ?
6/6/2011 © 2011 FAS.research 29
stable instable neutral
Role of KOL Change agent,
becomes a new attractor
Role of KOL Conservative,
keeps the systems thresholds and
boundaries stable
Role of KOL Agnostic / nihilistic,
everything is equally good / bad
![Page 30: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/30.jpg)
Influence: Cause or Effect?
Influence is the result of the sensitivity of a system towards variables from the environment.
The higher the instability (closeness to threshold) of a node the higher the (random) influence of the environment.
Examples for instability
– Buyers remorse
– Diminishing returns
– Crisis, confusion, insecurity
– Innovation, new products 6/6/2011 © 2011 FAS.research 30
![Page 31: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/31.jpg)
Stages of a network
6/6/2011 © 2011 FAS.research 31
Growth
Equilibrium
Crisis
Re-organization
![Page 32: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/32.jpg)
Sensitivity Parameter Attribute of Node:
– Horizontal centrality (betweeness)
– Vertical centrality (eigenvector)
– Degree of economic stress of organization
– Phase in the PLC and adaptive cycle
Attributes of Product:
– Therapeutic risks
– TNT, revenue and profit for prescribers
– Number of alternative products
Attribute of Network:
– Degree of cognitive dissonance and polarization in the therapeutic field
– Morphology: Structural Holes, Closure, Fold, Random Network
6/6/2011 © 2011 FAS.research 32
![Page 33: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/33.jpg)
Next Generation Strategy Map
6/6/2011 © 2011 FAS.research 33
![Page 34: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/34.jpg)
Summary
Network Mapping has proven to be a very powerful process to identify und understand different functional roles and their key players in the Pharma business.
Network Strategy Consulting requires to overcome a mythological framework to understand and manage influence.
Based on a modified, more realistic model of influence new insights about people and organizations with increasing or decreasing capacities to influence can be identified.
Future research and application at FAS will intensify the combination of node centric measures and models to measure the degree of sensitivity of the overall network.
6/6/2011 © 2011 FAS.research 34
![Page 35: Katzmair cop2011 - evidence based mapping](https://reader033.fdocuments.in/reader033/viewer/2022060200/5597f8bd1a28ab93608b47dc/html5/thumbnails/35.jpg)
Evidence Based Mapping Network Strategy Consulting in KOL Management, Marketing, Regulatory & Market Access.
www.fas-research.com mailto:[email protected]
6/6/2011 35 © 2011 FAS.research
Thank you for your Attention!